Monthly research recap
DMT research: January 2026
What January 2026's 13 new studies found, synthesized from the papers below. All DMT research →
The synthesis
Synthesized from 13 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for DMT, dimethyltryptamine, N,N-DMT, then ranked by relevance.
Research published in January 2026 on DMT and related compounds (5-MeO-DMT, ayahuasca alkaloids) spans preclinical, clinical, and theoretical domains. Preclinical studies in rodents and canines suggest potential therapeutic and safety signals—DMT reversed depressive-like behavior and cognitive deficits in stressed mice, and 5-MeO-DMT did not induce seizures in dogs—while a human PET study found a 12.5% increase in global brain glucose metabolism under DMT+harmine. However, evidence is largely preliminary, with small samples, animal models, and theoretical frameworks, and no large-scale clinical trials were reported.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines. 2026 | preclinical animal study | 11 | No effect | Intranasal 5-MeO-DMT produced dose-dependent behavioral signs but no seizures or epileptiform activity on continuous EEG in a canine model. |
| Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. 2026 | preclinical animal study | Supports | A single dose of DMT reversed depressive-like behavior and cognitive deficits in stressed mice, outperforming chronic fluoxetine in most domains, and enhanced adult-born granule cell integration. | |
| Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats 2026 | preclinical experimental study | Supports | DMT at 1 mg/kg combined with ventral root reimplantation significantly enhanced motor neuron survival, reduced glial reactivity, and upregulated GDNF expression after spinal root avulsion. | |
| A dispersive liquid-liquid microextraction method for the determination of ayahuasca alkaloids (N,N-dimethyltryptamine and β-carbolines) in human hair. 2026 | method development and validation study | 6 | Unclear | A DLLME-LC-MS/MS method successfully quantified DMT and β-carbolines in human hair, with β-carbolines generally detected at higher concentrations than DMT. |
| ALADIN v.O — Langorian Consciousness Field EFT (43 Hz): EEG Evidence from DMT Breakthrough & Meditation 2026 | multi-subject EEG analysis | Supports | A time-localized collapse of multifractal spectrum width was temporally locked with selective enhancement of gamma-band power near 43 Hz during peak conscious state transitions, replicable across subjects and conditions. | |
| 5-MeO-DMT Use in Humans: A Scoping Review of Peer-Reviewed Research 2026 | scoping review | 33 | Unclear | The review identified 33 studies on 5-MeO-DMT in humans, with most interventional studies using inhalation and showing large heterogeneity in design, dosing, and support. |
| Vigilance state dissociation induced by 5-MeO-DMT in mice. 2026 | observational cohort | Supports | 5-MeO-DMT induced a dissociated state in awake, moving mice characterized by cortical slow oscillations and pupil dilation, with initial REM suppression followed by overcompensation and attenuation of sleep deprivation-induced slow-wave rebound. | |
| Efectos subjetivos vinculados al consumo de Dimetiltriptamina (DMT) y su potencial como auxiliar terapéutico en adultos jóvenes de Hidalgo. 2026 | qualitative study | 7 | Supports | Participants reported subjective effects including heightened sensitivity, time distortion, and recall of past experiences, and some said DMT helped resolve personal conflicts or improved a stalled therapeutic process. |
| Changa and DMT Crystals, Engines of Cosmopolitan Neo-Shamanism 2026 | qualitative | Unclear | Describes three Brazilian ritual contexts involving DMT preparations and notes that changa, a smokable version, reportedly originated in Australia using acacia as the DMT source. | |
| Computational spirits: a neuroscientific account of psychedelic entity encounters. 2026 | theoretical or philosophical paper | Unclear | Argues that the reduced predictability of sensory perceptions under psychedelics inclines the brain to interpret perceptions as resulting from non-self-agentic sources, explaining entity encounters. | |
| The dying-moment dream hypothesis: heaven and hell as the brain's final dream. 2026 | theoretical or philosophical paper | Unclear | Proposes that near-death and afterlife experiences are a final endogenous simulation generated by the dying brain, not evidence of metaphysical realms. | |
| Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [¹⁸F]FDG-PET study 2026 | single-blind, crossover design | 14 | Supports | Global cerebral glucose metabolism increased by 12.5% under DMT+harmine versus placebo, with widespread cortical increases particularly in higher-order brain networks. |
| Micro-phenomenology of immersion and perceived presences under DMT. 2026 | experimental study with micro-phenomenological interview | 23 | Supports | Immersion under DMT follows a structured continuum from subtle to gross forms, with perceived presences emerging only after multisensory integration and 3D spatial characteristics have developed. |
Points of agreement
- DMT and 5-MeO-DMT show potential therapeutic effects in preclinical models, including antidepressant-like and neuroprotective actions.
- Human studies indicate DMT alters brain activity and metabolism, with increased glucose metabolism and specific EEG patterns.
- Subjective experiences under DMT are characterized by immersive and entity encounters, which are structured and reproducible.
Conflicts
- Preclinical findings in rodents suggest DMT has antidepressant and cognitive benefits, but human clinical evidence remains limited and heterogeneous.
- Theoretical papers propose mechanistic explanations for psychedelic phenomena, but these are not directly tested against empirical data.
Gaps
- Durability of effects beyond acute administration is not established.
- Most studies use small samples or animal models; large-scale human trials are lacking.
- Blinding and placebo controls are often inadequate, especially in qualitative and EEG studies.
- Dose-response relationships and optimal routes of administration are not fully characterized.
- Long-term safety and potential adverse effects in humans remain understudied.